BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

«Map Kinase Kinase 1

Below is an extended Map Kinase Kinase 1 research listing. Click here to return to the Map Kinase Kinase 1 main in depth entry.

Recent Publications on Map Kinase Kinase 1:

Chromatin-bound mitogen-activated protein kinases transmit dynamic signals in transcription complexes in beta-cells.
MAPK pathways regulate transcription through phosphorylation of...
Direct Link
1st October, 2008
Department of Pharmacology, University of Texas Southwestern Medical
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
BACKGROUND: In prostate cancer, the identification of drug combinations...
Direct Link
27th September, 2008
Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la
Emdogain stimulates matrix degradation by osteoblasts. 19th September, 2008
Departments of Biochemistry, Osaka Dental University, Osaka, Japan.
Retinoic acid induces apoptosis by a non-classical mechanism of ERK1/2 activation.
Even though RA is involved in differentiation and apoptosis of normal and...
Direct Link
30th August, 2008
Centro de Estudos em Estresse Oxidativo, Departamento de Bioquimica,
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Gefitinib (Iressa(R), ZD1839) is a selective epidermal growth factor...
Direct Link
20th August, 2008
Department of Internal Medicine, Hsinchu Hospital, Department of Health,
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.
Activating BRAF kinase mutations arise in approximately 7% of all human...
Direct Link
19th August, 2008
Center for Molecular Therapeutics, Massachusetts General Hospital Cancer
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.
Genetic lesions affecting a number of kinases and other elements within...
Direct Link
7th August, 2008
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer
Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma.
Schwannomas are tumors of the nervous system that occur sporadically and...
Direct Link
6th August, 2008
Clinical Neurobiology, Peninsula College for Medicine and Dentistry,
MEK1/2 induces STAT5-mediated germline transcription of the TCRgamma locus in response to IL-7R signaling. 29th July, 2008
Laboratory of Biological Protection, Department of Biological Responses,
Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells.
Mammalian cells express two closely related MEK isoforms, MEK1 and MEK2,...
Direct Link
25th July, 2008
Institute of Signaling Developmental Biology and Cancer, University of
Hepatocyte growth factor promotes cell survival by phosphorylation of BAD in gastric cancer cells. 25th July, 2008
Department of Hematology-Oncology, College of Medicine, Yeungnam
Differential regulation of rice mitogen activated protein kinase kinase (MKK) by abiotic stress.
Mitogen activated protein kinase cascade plays a crucial role in various...
Direct Link
16th July, 2008
National Institute for Plant Genome Research, Aruna Asaf Ali Road, New
Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. 11th July, 2008
Laboratoire de Cancerologie Experimentale et de Radiobiologie, Strasbourg,
ERK/MAPK regulation of the androgen responsiveness of breast cancer cells. 11th July, 2008
Department of Pathology, Royal Perth Hospital, Perth, Western Australia.
Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation.
Dysfunctional dendritic cells (DC) are common in cancer patients; however,...
Direct Link
4th July, 2008
Academic Unit of Clinical Oncology, University of Nottingham, City
 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

BioPortfolio logo

Valid XHTML 1.0 Transitional